Befotertinib

DB18844InvestigationalSmall molecule

Befotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive Patients With Advanced Egfr-mutant Lung Cancer).

Chemical structure of Befotertinib
Mechanism
Curator reviewed
Formula / weight
C29H32F3N7O2 · 567.617 g/mol (avg)
Also known as
2-propenamide, n-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)- · N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide
Code names
D-0316

Resolves to

Compound
UNII0XT2CPR891CAS1835667-63-4ChEMBLCHEMBL5095167
Structure
InChIKeyUSOCZVZOXKTJTI-UHFFFAOYSA-NSMILESCOC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(=N1)C1=CN(CC(F)(F)F)C2=CC=CC=C12
Targets
P00533EGFR
Transporters
P08183ABCB1Q9UNQ0ABCG2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
14Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Befotertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In